Bifidobacterium longum CECT 7894 Improves the Efficacy of Infliximab for DSS-Induced Colitis via Regulating the Gut Microbiota and Bile Acid Metabolism

Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation

(2022) Morgane M. Thibaut et al.   TRENDS IN MOLECULAR MEDICINE

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease

(2021) Yizhong Wang et al.   Gut Microbes

A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1

(2021) Wei Li et al.   Cell Host & Microbe

Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis

(2021) Zhen-Huan Yang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside

(2021) Min Yang et al.   Nutrients

Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases

(2021) Katarzyna Akutko et al.   Journal of Clinical Medicine

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

(2020) Akihiko Oka et al.   DIGESTIVE DISEASES AND SCIENCES

The microbiome and inflammatory bowel disease

(2020) Kerri L. Glassner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn’s disease

(2020) N S Ding et al.   Journal of Crohns & Colitis

Gut microbiota-derived metabolites as key actors in inflammatory bowel disease

(2020) Aonghus Lavelle et al.   Nature Reviews Gastroenterology & Hepatology

PICRUSt2 for prediction of metagenome functions

(2020) Gavin M. Douglas et al.   NATURE BIOTECHNOLOGY

Microbial network disturbances in relapsing refractory Crohn’s disease

(2019) Bahtiyar Yilmaz et al.   NATURE MEDICINE

Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases

(2019) Jason Lloyd-Price et al.   NATURE

Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

(2019) Konrad Aden et al.   GASTROENTEROLOGY

Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2

(2019) Evan Bolyen et al.   NATURE BIOTECHNOLOGY

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

(2019) Joana Torres et al.   Journal of Crohns & Colitis

The MetaCyc database of metabolic pathways and enzymes - a 2019 update

(2019) Ron Caspi et al.   NUCLEIC ACIDS RESEARCH

Gut Microbiota Dysbiosis Is Associated with Altered Bile Acid Metabolism in Infantile Cholestasis

(2019) Yizhong Wang et al.   mSystems

Administration of the hyper-immune bovine colostrum extract IMM-124E ameliorates experimental murine colitis

(2018) Marianne R Spalinger et al.   Journal of Crohns & Colitis

Characteristics of Faecal Microbiota in Paediatric Crohn’s Disease and Their Dynamic Changes During Infliximab Therapy

(2017) Yizhong Wang et al.   Journal of Crohns & Colitis

Chemically induced mouse models of acute and chronic intestinal inflammation

(2017) Stefan Wirtz et al.   Nature Protocols

Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition

(2016) Maria K. Magnusson et al.   Journal of Crohns & Colitis

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

(2016) Alon D. Levin et al.   Journal of Crohns & Colitis

DADA2: High-resolution sample inference from Illumina amplicon data

(2016) Benjamin J Callahan et al.   NATURE METHODS

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials

(2015) Maria Jose Saez-Lara et al.   Biomed Research International

Bile acids and the gut microbiome

(2014) Jason M. Ridlon et al.   CURRENT OPINION IN GASTROENTEROLOGY

Finding the Missing Links among Metabolites, Microbes, and the Host

(2014) Pieter C. Dorrestein et al.   IMMUNITY

Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohnʼs Disease

(2014) Sylvie Rajca et al.   INFLAMMATORY BOWEL DISEASES

Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death

(2014) Debby Laukens et al.   LABORATORY INVESTIGATION

Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases

(2012) Henri Duboc et al.   GUT

Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages

(2011) Raja Atreya et al.   GASTROENTEROLOGY

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

Genetics and pathogenesis of inflammatory bowel disease

(2011) Bernard Khor et al.   NATURE

Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner

(2010) Anne Christine W. Vos et al.   GASTROENTEROLOGY

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE